Cantitate/Preț
Produs
Total produse
Vezi coșul
Clinical Use of Immunoglobulins de Volker Wahn

Clinical Use of Immunoglobulins: UNI-MED SCIENCE

Autor Volker Wahn, Jordan Orange
en Limba Engleză Hardback – 10 iun 2013
Immunoglobulins play an essential role in the human immune system. Therapeutic immunoglobulin truly represents a global resource and the web connecting clinical research, basic research, manufacturing and advocacy truly span the globe.Now five years have passed since the first English edition of "Clinical Use of Immunoglobulins". Much progress has occurred in the field over that time: new clinical indications, new efficacy and outcome data, novel insights into mechanisms of action and new preparations of therapeutic immunoglobulin.This new 2nd edition features two entirely new chapters one covering the adverse effects of immunoglobulin therapy (Chapter 3) and a second covering dermatologic diseases (Chapter 16). All previous topics are included and have been updated. In aggregate, the volume provides comprehensive perspective on therapeutic immunoglobulin.
Citește tot Restrânge

Din seria UNI-MED SCIENCE

  • 5% Dyslipoproteinämien - Strategien zu Diagnostik und Therapie
    Preț: 22809 lei
  • 5% Praktisches Handbuch der Brachytherapie
    Preț: 28953 lei
  • 5% Chronische Herzinsuffizienz mit reduzierter Auswurffraktion (HFrEF)
    Preț: 22581 lei
  • 5% Morbus Cushing - Diagnostik und Therapie mit Fallbeispielen
    Preț: 4923 lei
  • 5% Aktuelle Therapieoptionen beim systemischen Lupus erythematodes
    Preț: 4408 lei
  • 5% Palliativmedizin - Lehrbuch für Ärzte, Psychosoziale Berufe und Pflegepersonen
    Preț: 40515 lei
  • 5% Therapieleitfaden Transsexualität
    Preț: 27937 lei
  • 5% Impfratgeber - Impfempfehlungen für Kinder, Jugendliche und Erwachsene
    Preț: 23784 lei
  • 5% Thrombotische Mikroangiopathien
    Preț: 22288 lei
  • 5% Kurzlehrbuch Hals-Nasen-Ohren-Heilkunde
    Preț: 25652 lei
  • 5% Die B-Vitamine Folsäure, B6 und B12 in der Prävention
    Preț: 17966 lei
  • 5% Grundlagen und klinische Anwendung der Prostataarterien-Embolisation (PAE) bei benigner Prostatahyperplasie
    Preț: 5015 lei
  • 5% Therapie des fortgeschrittenen Parkinson-Syndroms
    Preț: 4699 lei
  • 5% Das metastasierte Urothelkarzinom
    Preț: 22614 lei
  • 5% Glomerulonephritiden - Krankheitsbilder und nephrologische Therapiekonzepte
    Preț: 23289 lei
  • 5% Praktische Aspekte der Heimbeatmung
    Preț: 27150 lei
  • 5% Perspektiven in der Therapie der ¿-Hämoglobinopathien
    Preț: 23090 lei
  • 5% Moderne Praxis der Migränetherapie - bewährte Strategien und Innovationen
    Preț: 23651 lei
  • 5% ANCA-assoziierte Vaskulitiden: GPA, MPA und EGPA
    Preț: 22903 lei
  • 5% Diagnostik und moderne Therapie des Cholangiokarzinoms (CCA)
    Preț: 22662 lei
  • 5% Colitis ulcerosa - Morbus Crohn
    Preț: 23837 lei
  • 5% Chemotherapie und febrile Neutropenie - Probleme und Konzepte
    Preț: 4655 lei
  • 5% Niemann-Pick disease
    Preț: 12760 lei
  • 5% Pompe Disease
    Preț: 5789 lei
  • 5% Neurodermitis - Ein Leitfaden für Ärzte und Patienten
    Preț: 22874 lei
  • 5% Neuropädiatrie
    Preț: 76837 lei
  • 5% Schock - Moderne klinische Therapiekonzepte
    Preț: 12186 lei
  • 5% Erythropoese-Stimulation bei renaler Anämie
    Preț: 22581 lei
  • 5% Botulinumtoxin in der Augenheilkunde
    Preț: 4699 lei
  • 5% IVUS (IntraVascular UltraSound) Image Guidance for Treatment of Aorto-Iliac Pathologies
    Preț: 25677 lei
  • 5% Lymphödem bei Brustkrebs - was tun?
    Preț: 12394 lei
  • 5% Das Multiple Myelom - Diagnose und Therapie
    Preț: 27689 lei
  • 5% Mutation-specific therapies in cystic fibrosis
    Preț: 29059 lei
  • 5% Mukopolysaccharidosen und ähnliche lysosomale Erkrankungen - Ein Leitfaden für Betroffene, Familien, Ärzte und Angehörige der Pflegeberufe
    Preț: 24263 lei
  • 5% Sequenztherapie der Osteoporose - Theorie und moderne Praxiskonzepte
    Preț: 27041 lei
  • 5% Klinische Toxikologie für die Intensivmedizin: Noxen, Symptome, Therapie, Analytik
    Preț: 62033 lei
  • 5% Questions Urologiques en Pratique
    Preț: 25568 lei
  • 5% Das HER2-positive metastasierte Mammakarzinom - Aktuelle Behandlungskonzepte
    Preț: 4512 lei
  • 5% SGLT-2-Inhibition, Diabetes und Herz - Moderne medizinische Konzepte
    Preț: 22675 lei
  • 5% Methotrexat bei Autoimmunerkrankungen - Moderne Therapiekonzepte in der Rheumatologie, Dermatologie und Gastroenterologie
    Preț: 5350 lei
  • 5% Atem- und Bewegungstherapie bei Pulmonaler Hypertonie
    Preț: 18346 lei
  • 5% Pulmonale Rehabilitation nach Laryngektomie
    Preț: 22874 lei
  • 5% Zellschutz - Entgiftung - Prävention: Die gesundheitliche Bedeutung von Glutathion
    Preț: 17585 lei
  • 5% X-chromosomale Hypophosphatämie - Phosphatdiabetes - XLH
    Preț: 5800 lei
  • 5% Diagnostik und Therapie der Spinalen Muskelatrophie
    Preț: 22655 lei
  • 5% Medikamentöse Therapie des Morbus Parkinson
    Preț: 5877 lei
  • 5% Die Blastische plasmazytoide dendritische Zellneoplasie (BPDCN) - Pathogenese, Diagnostik und Therapie
    Preț: 4719 lei
  • 5% Mikroskopische Kolitis
    Preț: 4532 lei
  • 5% Vitamin-D-Mangel - Aktuelle Diagnostik und Prophylaxe in Fallbeispielen
    Preț: 18192 lei
  • 5% Das Multiple Myelom (Plasmozytom) - Diagnose und Therapie
    Preț: 23230 lei

Preț: 27074 lei

Preț vechi: 28499 lei
-5% Nou

Puncte Express: 406
Preț estimativ în valută:
5181€ • 5463$ • 4313£

Carte indisponibilă temporar


Wish list
Gift list
Am citit!
Adaugă în listă
Doresc să fiu notificat când acest titlu va fi disponibil:
Trimite
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781848152021
ISBN-10: 1848152027
Pagini: 252
Dimensiuni: 174 x 246 x 15 mm
Greutate: 0.6 kg
Ediția:2nd edition.
Editura: Uni-Med Verlag Ag
Seria UNI-MED SCIENCE

Cuprins

1. The Biology of Antibody Synthesis 221.1. Antibodies - the Molecule 231.2. Antibodies - Mechanism of Action 241.2.1. IgM 251.2.2. IgD 261.2.3. IgG 261.2.4. IgA 261.2.5. IgE 271.3. The B Cell Repertoire 271.4. Peripheral B Cell Activation and Differentiation 281.5. Isotype Switching 301.6. Conclusion 311.7. References 322. Pathogen Safety of Immunoglobulin Preparations 332.1. Plasma Source 352.1.1. Whole Blood or Plasma Donations 352.1.2. Selection of Donors and Mass Screening of Donations 352.2. Evaluating and Validating the Virus Safety of Immunoglobulin G Preparations 382.3. Virus Reduction During Fractionation of Immunoglobulin Preparations 402.3.1. Partitioning 402.3.2. Inactivation 422.3.3. The Introduction of Large-Scale Virus Filtration 432.3.4. Additional Virus Reduction and Inactivation Methods 452.4. Prion Safety of IVIG/SCIG 452.4.1. Measures to Reduce the Theoretical Risk of vCJD Transmission by Immunoglobulin Preparations 462.5. Cleaning and Traceability 482.5.1. Cleaning of Equipment in Contact with Product Prevent Carryover of Potentially Present Pathogens from Batch to Batch 482.5.2. Traceability 482.6. Pharmacovigilance, Post-Marketing Studies and Surveillance Programs - the Final Proof of Pathogen Safety of a Blood or Plasma Product 482.6.1. Virus Safety 482.6.2. The Risk of Transmission of Classic/Sporadic CJD 492.6.3. The Risk of Transmission of Variant CJD 492.7. Emerging Pathogens 492.8. Web-sites worth Reviewing for Additional Information 512.9. References 513. Adverse Effects of Human Immunoglobulin Therapy 583.1. History of Immune Globulin Treatment 583.2. Immunoglobulin Products 583.3. Reactions to Intramuscular and Subcutaneous Immunoglobulins 583.3.1. IGIM Reactions 583.3.2. IGSC Reactions 593.4. Reactions to Intravenous Immunoglobulin 593.5. Types of Reactions 613.5.1. Immediate Reactions 613.5.2. Delayed Reactions 623.6. Summary 653.7. References 654. Passive Immunoprophylaxis with Immunoglobulins 704.1. Definition 704.2. General Principles 704.3. Specific Immunoglobulin Preparations 704.4. Instructions for Use, Side Effects, Contraindications, Interactions 704.5. Indications for Passive Immunoprophylaxis 724.5.1. Hepatitis A 724.5.1.1. Principles 724.5.1.2. Passive Immunoprophylaxis 724.5.2. Hepatitis B 734.5.2.1. Principles 734.5.2.2. Passive Immunoprophylaxis 734.5.3. Measles 744.5.3.1. Principles 744.5.3.2. Passive Immunoprophylaxis 744.5.4. Rubella 744.5.4.1. Principles 744.5.4.2. Passive Immunoprophylaxis 744.5.5. Varicella 754.5.5.1. Principles 754.5.5.2. Passive Immunoprophylaxis 754.5.6. Cytomegalovirus Infection 764.5.6.1. Principles 764.5.6.2. Passive Immunoprophylaxis 764.6. Monoclonal Antibodies 764.6.1. Respiratory Syncytial Virus - Principles 764.6.2. Passive Immunoprophylaxis 764.7. Bacterial Toxins 774.7.1. Botulism 774.7.2. Immunoprophylaxis 774.7.3. Rabies 774.7.4. Diphtheria Toxin 784.7.5. Tetanus 784.8. References 785. Sepsis in Neonates: Prevention and Adjuvant Therapy with Intravenous Immunoglobulin 805.1. Immunoglobulin as Prophylaxis in Neonatal Infections 815.2. Immunoglobulin as Adjuvant Therapy for Neonatal Infections 845.3. Additional Considerations 855.4. Recent Developments 865.5. Summary 885.6. References 896. Application of Immunoglobulins in Other Infections 926.1. Exacerbation in Cystic Fibrosis 926.2. Infection with Respiratory Syncytial Virus 936.3. Infection with Rotaviruses 946.4. Bacterial Meningitis 946.5. Bacterial Sepsis 956.6. Streptococcal Toxic Shock-Like Syndrome 956.7. Hemolytic Uremic Syndrome 956.8. Recurrent Clostridium Difficile Colitis 966.9. Infant Botulism 976.10. References 977. Use of Immunoglobulins in Congenital and Acquired Immunodeficiencies 997.1. Definitions 997.1.1. Primary Immunodeficiencies with B Cell Defects 997.1.2. Secondary Immunodeficiencies with B-Cell Defects 1027.2. Frequency of Immunodeficiencies 1027.3. Etiology/Pathogenesis of Immunodeficiencies 1027.4. Clinical Findings in Humoral Immunodeficiencies 1027.5. Replacement Therapy with Immunoglobulins 1037.5.1. Immunoglobulin Therapy for Primary Immunodeficiencies 1047.5.1.1. Indications of IgG replacement in immunodeficiencies 1047.5.1.2. Monitoring of Immunoglobulin Therapy 1057.5.1.3. Infections Despite Immunoglobulin Replacement 1057.5.1.3.1. Acute Respiratory Infections 1057.5.1.3.2. Chronic Respiratory Infections 1067.5.2. Immunoglobulin Therapy for Secondary Immunodeficiencies 1067.5.2.1. Human Immunodeficiency Virus (HIV) 1067.6. Summary and Conclusions 1067.7. References 1078. IVIG Treatment of Secondary Immune Deficiencies in Adults 1098.1. Immunity and Infection in Chronic Lymphocytic Leukemia and Multiple Myeloma 1098.2. Therapy with IVIG in Chronic Lymphocytic Lymphoma and Multiple Myeloma 1108.3. Hematopoetic Stem Cell Transplantation 1128.4. References 1129. Immunomodulation with Immunoglobulins: Mechanisms 1149.1. Release of Platelets from the Reticuloendothelial System (ITP) 1159.2. Effects on Platelet-Associated IgG (ITP) 1159.3. Accelerated Elimination of Circulating and Tissue-Bound Immune Complexes 1159.4. Interaction with Fc Receptors (FcR) 1159.5. Inhibition of Cell Adhesion by Natural RGD Antibodies 1189.6. Effects on the Complement System 1189.7. Disturbance of (Auto-)Antigen Presentation and Recognition 1189.8. Interference with the Idiotype-Anti-Idiotype Network (anti-id-Ab) 1209.9. Effects on Cytokines 1209.9.1. Neutralization of Inflammatory Cytokines 1209.9.2. Induction of Regulatory Cytokines and Receptor Antagonists 1219.9.3. Inhibition of Cellular Responses to Interferon-g by Suppression of Expression of the IFNGR2 Receptor 1219.9.4. Increased Steroid Mediated Anti-Inflammatory Effects 1229.10. Neutralization of Superantigens 1229.11. Effects on Apoptosis 1229.12. Effects on T cells 1239.13. Summary 1239.14. References 12310. Use of Immunoglobulins in Hematological Cytopenias 12710.1. Thrombocytopenia 12710.1.1. Acute Immune Thrombocytopenia 12710.1.2. Neonatal Alloimmune Thrombocytopenia (AIT) 12910.1.3. Maternal Autoimmune Thrombocytopenia During Pregnancy 13010.1.4. Posttransfusion Purpura (PTP) 13110.1.5. Platelet Transfusions in Marked Alloimmunization 13110.1.6. Heparin-induced Thrombocytopenia 13110.1.7. Thrombocytopenia in the Hemolytic-Uremic Syndrome 13110.1.8. Thrombotic Thrombocytopenic Purpura (Moschcowitz Syndrome) 13110.1.9. HIV-Associated Thrombocytopenia 13210.1.10. Chronic ITP 13210.1.11. SLE-Associated Thrombocytopenia 13410.1.12. Thrombocytopenia in Primary Antibody Deficiency Syndrome 13410.2. Immune Hemolytic Anemia 13510.2.1. Rhesus-Induced Alloimmune Hemolysis 13510.2.2. ABO Isoimmune Hemolysis 13510.2.3. Autoimmune Hemolytic Anemia and Evans Syndrome 13510.3. Bone Marrow Aplasia 13610.3.1. Erythroid Aplasia, Autoimmune Erythroblastopenia, Pure Red Cell Aplasia (PRCA) 13610.4. Infection-Associated Hemophagocytosis Syndrome 13610.5. Immune Neutropenia: Allo- and Autoimmune Neutropenia 13710.6. Summary 13810.7. References 13811. Further Applications of Immunoglobulin Therapy in Pediatric Hematology/Oncology 14411.1. Polyvalent Immunoglobulin Therapy in Pediatric Oncology Patients Undergoing Chemotherapy 14411.2. Application of Polyvalent Immunoglobulins in Allogeneic Hematopoietic Stem Cell Transplantation 14511.3. Application of Polyvalent Immunoglobulins in Hemophilia A/B with Inhibitor 14711.4. References 14712. Use of Immunoglobulins in Rheumatologic Disorders and Systemic Autoimmunopathies 15012.1. Juvenile Idiopathic Arthritis 15112.2. Rheumatoid Arthritis 15412.2.1. Felty Syndrome and Macrophage Activation Syndrome (MAS) 15412.2.2. Systemic Lupus Erythematosus 15512.3. Antiphospholipid Syndrome (APS) 15712.4. Scleroderma, Mixed Connective Tissue Disorder 15812.5. Crohn's Disease and Ulcerative Colitis 15912.6. Uveitis 16012.7. Summary and Concluding Remarks 16012.8. References 16113. Use of Immunoglobulins for Kawasaki Disease and other Vasculitic Diseases 16513.1. Kawasaki Disease (KD) 16513.1.1. Epidemiology and Pathogenesis 16513.1.2. Clinical Manifestations 16613.1.3. Efficacy of HDIVIG in the Initial Treatment 16713.1.4. Time Point of Primary HDIVIG Application 16813.1.5. Influence of IVIG Preparation on Treatment Efficacy 16813.1.6. Role of Corticosteroids in the Initial Treatment 16813.1.7. Second HDIVIG in Patients Non-Responsive to Initial Treatment 16913.1.8. Steroid Treatment in IVIG-Resistant Patients 16913.1.9. Alternative Treatment Approaches in IVIG-Resistant Patients 17013.2. Polyarteritis Nodosa 17013.3. ANCA-positive Vasculitis [Granulomatosis with Polyangiitis (GPA, Wegener's), Microscopic Polyangiitis) 17013.4. Churg-Strauss Syndrome 17113.5. IgA Nephropathy, Henoch-Schoenlein Purpura 17213.6. Livedo Vasculitis 17213.7. Vasculitic Complications in Collagen Diseases 17213.8. Summary 17213.9. References 17314. The Use of Immunoglobulins for Neurological Diseases in Children and Adults 17714.1. Multiple Sclerosis 17714.2. Epilepsy 17914.3. Non-Epileptic Encephalopathies in Children and Adolescents 18314.4. Other CNS Diseases 18414.5. Paraneoplastic Syndromes 18514.6. Inflammatory Polyneuropathies 18614.7. Myasthenia Gravis 19314.8. Dermatomyositis, Polymyositis, Inclusion Body Myositis 19614.9. References 19815. Use of Intravenous Gammaglobulin (IVIG) in Kidney Transplantation 20815.1. Desensitization for ABO Incompatible Transplantation 20815.2. Immunomodulation with IVIG: Desensitization of Highly-HLA Sensitized Patients 20915.2.1. Clinical Use of IVIG in Kidney Transplantation 20915.2.2. The NIH IGO2 Study 20915.2.3. Low-dose Intravenous Immunoglobulin and Plasmapheresis 21015.2.4. IVIG + Rituximab for Desensitization 21115.2.5. Complications and Cost of IVIG Therapy 21115.2.6. IVIG and Acute Myocardial Infarction (AMI) 21215.2.7. IVIG and Acute Renal Failure (ARF) 21215.2.8. IVIG and Hemolytic Anemia 21215.2.9. Economic Analysis of IVIG + Rituximab Desensitization Therapy 21315.3. Adjunctive Therapy 21415.3.1. Splenectomy and Anti-CD20 21415.3.2. Kidney Paired Donation 21415.4. Mechanism of Action of IVIG 21515.5. Conclusion 21615.6. References 21616. The Use of Immunoglobulins for Dermatologic Disease 21916.1. Pemphigus 21916.2. Bullous Pemphigoid 22216.3. Mucous Membrane Pemphigoid 22316.4. Epidermolysis Bullosa Acquisita 22416.5. Linear Iga Bullous Disease 22416.6. Pemphigoid Gestationis 22516.7. Pyoderma Gangrenosum 22616.8. Chronic Urticaria 22616.9. Toxic Epidermal Necrolysis 22716.10. References 22817. Use of Immunoglobulins in Allergic Diseases 23117.1. Bronchial Asthma 23117.2. Atopic Dermatitis 23217.3. Chronic Urticaria 23317.4. Possible Mechanism of Action in Allergic Diseases 23317.5. References 23418. Intravenous Immunoglobulin in the Prevention of Recurrent Miscarriage 23718.1. Studies of IVIG Treatment of RM 23718.2. Patient Subsets and Treatment Protocols may Determine Outcome of IVIG Studies 23818.2.1. Patient Subsets 23818.2.2. Treatment Protocols 23918.3. Negative Aspects of IVIG Use in RM 23918.4. Conclusions 24018.5. References 24119. Further Indications for Intravenous Immunoglobulins 24319.1. Graves-Basedow Disease (GBD) / Autoimmune Hyperthyroidism 24319.2. Bullous Pemphigoid and Pemphigus Vulgaris 24319.3. Toxic Epidermal Necrolysis (TEN, Lyell's Syndrome) and Stevens-Johnson's Syndrome 24419.4. Toxic Shock Syndrome / Necrotising Fasciitis 24619.5. Myocarditis and Congestive Chronic Heart Failure 24619.6. Severe Acute Respiratory Syndrome (SARS) 24719.7. References 247Index 250